Essity reported on July 16, 2026, that retail incontinence products remained a strong growth category in the second quarter, while healthcare incontinence products also performed positively. The company said it introduced further developments in the TENA range during the quarter as part of product launches across its business areas.
Group net sales increased 2.6% to SEK 35,061 million. Organic sales growth was 0.3%, comprising a 1.4% volume increase and a 1.1% negative contribution from price and mix. EBITA excluding items affecting comparability was SEK 4,685 million, with the corresponding margin declining 0.3 percentage points to 13.4%.
Essity said Health & Medical, Personal Care and Professional Hygiene contributed positively to organic growth, while Consumer Tissue sales fell. It cited higher input and transport costs and said it was responding through price increases and cost savings. The company also described using AI to shorten product-development lead times and improve efficiency, alongside continued investment in brands, innovation and growth.